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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 3 g/day 
plant stanols as plant stanol esters and lowering blood LDL-cholesterol and 
reduced risk of (coronary) heart disease pursuant to Article 14 of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Raisio Nutrition Ltd, submitted pursuant to Article 14 of Regulation 
(EC) No 1924/2006 via the Competent Authority of Finland, the Panel on Dietetic Products, Nutrition 
and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related 
to 3 g/day plant stanols as plant stanol esters per day and lowering blood LDL-cholesterol by 12 % 
and reduced risk of (coronary) heart disease. The applicant has further requested that the minimum 
duration to obtain the effect be stated to be one to two weeks, and that the claims be authorised for an 
extended range of foods, including yellow fat spreads, dairy products, cheese, rye bread, oatmeal, 
fermented soy milk based products (drinkable and spoonable yoghurt-type products), and oat based 
milk drinks. The applicant provided an unpublished meta-analysis with 18 randomised, controlled 
human studies on the LDL-lowering efficacy of  plant stanol esters at intakes between 2.7 to 3.3 g per 
day plant stanols. On the basis of the data presented, the Panel concludes that plant stanol esters at a 
daily intake of 3 g plant stanols (range 2.7 g to 3.3 g) in matrices approved by Regulation (EC) No 
376/2010 (yellow fat spreads, dairy products, mayonnaise and salad dressings) lowers LDL-
cholesterol by 11.4 % (95% CI: 9.8 – 13.0), that the minimum duration required to achieve the 
maximum effect of plant stanol esters on LDL-cholesterol lowering is two to three weeks, and that 
while plant stanol esters added to foods such as margarine-type spreads, mayonnaise, salad dressings, 
and dairy products such as milk, yoghurts including low-fat yoghurts, and cheese have been shown 
consistently to lower blood LDL-cholesterol levels, the size of the cholesterol-lowering effect of plant 
stanols added to other food formats is less well established. 
                                                     
1  On request from the Competent Authority of Finland following an application by Raisio Nutrition Ltd, Question No 
EFSA-Q-2011-00851, adopted on 26 April 2012. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Two members of the Panel did not participate in the discussion on the subject 
referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of 
interests. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis 
Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, 
Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van 
Loveren, Hans Verhagen and EFSA‟s staff member Wolfgang Gelbmann for the preparatory work for this scientific 
opinion. 
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SUMMARY 
Following an application from Raisio Nutrition Ltd, submitted pursuant to Article 14 of Regulation 
(EC) No 1924/2006 via the Competent Authority of Finland, the Panel on Dietetic Products, Nutrition 
and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related 
to 3 g plant stanol esters per day and lowering blood LDL-cholesterol by 12 % and reduced risk of 
(coronary) heart disease. The applicant has further requested that the minimum duration for the effect 
be stated to be one to two weeks, and that the claims be authorised for an extended range of foods, 
including yellow fat spreads, dairy products, cheese, rye bread, oatmeal, fermented soy milk based 
products (drinkable and spoonable yoghurt-type products), and oat based milk drinks. 
The Panel notes that the applicant‟s request specifically relates to the amendment of an already 
authorised claim laid down in Regulation (EC) No 376/2010 so that it would refer to an intake of 3.0 
g/d of plant stanol esters added to an extended range of foods which would lead to an LDL-
cholesterol lowering effect of  12 % within 1 - 2 weeks. The application included a request for the 
protection of proprietary data. 
 
The applicant provided an unpublished meta-analysis on 18 randomised, controlled human studies on 
the LDL-lowering efficacy of  plant stanols (as plant stanol ester) at intakes between 2.7 to 3.3 g per 
day in matrices approved by the European Commission. In this analysis the relative pooled LDL-
cholesterol lowering effect was 11.4 % (95% CI, 9.8 - 13.0 %).  The Panel notes some limitations of 
the applicant‟s meta-analysis that contribute to uncertainty of the estimate of the LDL-cholesterol 
lowering effect (e.g. the study quality not being taken into account, and the estimation of the relative 
net changes of LDL-cholesterol levels and variance parameters which were not reported in most of the 
original articles).  
The applicant claimed that the minimum duration required for efficacy was one to two weeks. In two 
of three treatment arms, in which the earliest LDL-cholesterol measurement was made after one week 
of intervention with plant stanol ester enriched foods, the maximum LDL-cholesterol lowering effect 
was achieved already after one week of intervention; in the third study the maximum effect was 
achieved after two intervention weeks. In four out of eight treatment arms in which the earliest LDL-
cholesterol measurement was made after two weeks of the plant stanol ester intervention the 
maximum LDL-cholesterol lowering effect was attained after two weeks of intervention, while in the 
four other treatment arms most of the reduction was already achieved after two weeks. The Panel 
considers that the minimum duration required to achieve the maximum effect of plant stanols on 
LDL-cholesterol lowering is two to three weeks. 
With regards to the proposed conditions of use, the applicant suggested that the food matrices should 
not be limited to those specified in Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, 
mayonnaise and salad dressings) and that the claimed effect can also be achieved with other matrices 
(rye bread, oatmeal, fermented soy milk based products (drinkable and spoonable yoghurt-type 
products), and oat based milk drinks). The Panel notes that all of the 18 treatment arms analysed in 
the meta-analysis used matrices specified in Commission Regulation (EC) No 376/2010 and that no 
human intervention study has been provided by the applicant to demonstrate that 3 g plant stanols 
consumed with other food matrices can lower blood LDL-cholesterol by 12 %.  
On the basis of the data presented, the Panel concludes that plant stanol esters at a daily intake of 3 g 
plant stanols (range 2.7 g to 3.3 g) in matrices approved by Regulation (EC) No 376/2010 (yellow fat 
spreads, dairy products, mayonnaise and salad dressings) lowers LDL-cholesterol by 11.4 % (95% CI: 
9.8 – 13.0), that the minimum duration required to achieve the maximum effect of plant stanol esters 
on LDL-cholesterol lowering is two to three weeks, and that while plant stanol esters added to foods 
such as margarine-type spreads, mayonnaise, salad dressings, and dairy products such as milk, 
yoghurts including low-fat yoghurts, and cheese have been shown consistently to lower blood LDL-
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cholesterol levels, the size of the cholesterol-lowering effect of plant stanols added to other food 
formats is less well established.  
The Panel could have reached these conclusions without considering the unpublished meta-analysis 
claimed as proprietary by the applicant. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children‟s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 29/06/2011. 
 The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction. 
 The scientific evaluation procedure started on 10/07/2011. 
 On 12-14/10/2011 and on 13-15/12/2011, the NDA Panel agreed on a list of questions for the 
applicant to provide additional information to accompany the application, and the clock was 
stopped on 10/11/2011 and 19/12/2011 in compliance with Art. 16(1) of Regulation (EC) No 
1924/2006.  
 On 05/12/2011 and on 30/12/2011, EFSA received the requested information as submitted by 
the applicant and the clock was restarted.  
 During its meeting on 25-27/04/2012, the NDA Panel, after having evaluated the overall data 
submitted, adopted an opinion on the scientific substantiation of a health claim related to 3 
g/day plant stanols as plant stanol esters and lowering blood LDL-cholesterol by 12 % and 
reduced risk of (coronary) heart disease. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to 3 g plant stanol esters and lowering 
blood LDL-cholesterol by 12 % and reduced risk of (coronary) heart disease. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of plant stanol esters, a positive assessment of its safety, nor a decision on whether plant stanol esters 
is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
                                                     
4 European Parliament and Council (2006). Regulation (EC) No 1924/2006 of the European Parliament and of the Council 
of 20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union OJ L 404, 
30.12.2006. Corrigendum OJ L 12, 18.1.2007, p. 3–18. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Raisio Nutrition Ltd. P.O. Box 101 (Rasionkaari 55), FI-21201 
Raisio, Finland. 
The application indicates confidential and proprietary data. The applicant claims confidentiality and 
proprietary rights for the data related to composition, product certificate of analysis properties and 
physical properties, batch to batch analyses, manufacturing process, stability information, for an 
unpublished study report (Hallikainen et al., 2010) of a published study (Hallikainen et al., 2011) and 
an unpublished meta-analysis which has been conducted on published studies. 
Food/constituent as stated by the applicant 
Plant stanol ester produced by esterification of plant stanols with fatty acids derived from food-grade 
vegetable oils or blends of vegetable oils. According to the applicant, the maximum proportion of 
campestanol from total plant stanols is 32 % in the products related to this application. 
Health relationship as claimed by the applicant 
Consumption of 3 g/day plant stanols (as plant stanol ester) reduces LDL-cholesterol by 12 %. 
Reducing LDL-cholesterol reduces the risk of coronary heart disease.  
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “The daily consumption of 3 g 
plant stanols in ester form has been shown to reduce blood cholesterol by 12 %.  High cholesterol is a 
risk factor in the development of coronary heart disease.” 
Specific conditions of use as proposed by the applicant 
The target population is broad and includes male and female adults with elevated (not optimal) LDL-
cholesterol levels who need and want to lower their blood cholesterol, currently receiving or not 
receiving pharmacological therapy for dyslipidaemia.  
To achieve a LDL-cholesterol reduction of 12 %, 3 g of plant stanols (as plant stanol ester) must be 
consumed daily. The foods to which plant stanol ester are added are commonly consumed as part of 
the daily diet. Currently marketed products with plant stanol ester include yellow fat spreads, dairy 
products, cheese, rye bread, oatmeal, fermented soy milk based products (drinkable and spoonable 
yoghurt-type products), and oat based milk drinks. Given the variety of plant stanol ester containing 
foods available, the consumption of 3 g/day plant stanols, either as a single dose or in divided doses, 
can be reasonably consumed as part of a balanced diet.   
According to the applicant, the minimum duration required for efficacy is 1 to 2 weeks. The LDL-
cholesterol lowering efficacy of plant stanol ester in matrices other than those specified in Regulation 
(EC) No 376/2010 is comparable to the efficacy of matrices approved for quantitative plant stanol 
ester claims; thus, the food matrices for plant stanol ester should not be limited to yellow fat spreads, 
dairy products, mayonnaise, and salad dressings.  
As per Regulation (EC) No 608/2004, foods and food ingredients with added phytosterols, phytosterol 
esters, phytostanols and/or phytostanol esters shall have an “easily visible and legible statement that 
the product may not be nutritionally appropriate for pregnant and breastfeeding women and children 
under the age of 5 years”.     
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ASSESSMENT 
1. INTRODUCTION 
The applicant has proposed the health claim “The daily consumption of 3 g plant stanols in ester form 
has been shown to reduce blood cholesterol by 12 %.  High cholesterol is a risk factor in the 
development of coronary heart disease.”  The applicant has further requested that the minimum 
duration for the effect be stated to be 1-2 weeks, and that the claims be authorised for a range of 
foods, including yellow fat spreads, dairy products, cheese, rye bread, oatmeal, fermented soy milk 
based products (drinkable and spoonable yoghurt-type products), and oat based milk drinks. The 
Panel notes that a similar health claim has already been authorised by Regulation (EC) No 376/2010 
amending Regulation (EC) No 983/2009. The authorised claim is: „Plant stanol esters have been 
shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the development of 
coronary heart disease.‟ The conditions of use of the claim are: „Information to the consumer that the 
beneficial effect is obtained with a daily intake of 1.5 – 2.4 g plant stanols.  Reference to the 
magnitude of the effect may only be made for foods within the following categories: yellow fat 
spreads, dairy products, mayonnaise and salad dressings. When referring to the magnitude of the 
effect, the entire range „7 to 10 %‟ and the duration to obtain the effect „in 2 to 3 weeks‟ must be 
communicated to the consumer‟. 
 
The Panel notes that the applicant‟s request specifically relates to the amendment of the authorised 
claim, i.e. that the intake of 3.0 g/d of plant stanol esters added to an extended range of foods leads to 
an LDL-cholesterol lowering effect of  12 % within 1 - 2 weeks.  
 
The Panel recalls the conclusions from its earlier opinion on plant sterols/stanols and lowering LDL-
cholesterol (EFSA, 2009) that (i) the efficacy for lowering LDL-cholesterol is similar for plant sterols 
and plant stanols, that (ii) 1.5 - 1.9 g and 2.0 - 2.4 g plant sterols/plant stanols per day was observed to 
lower blood LDL-cholesterol by an average of 8.5 % and 8.9 %, respectively, and that for an intake of 
1.5 - 2.4 g/d an average reduction of between 7 and 10.5 % can be expected, that (iii) the blood LDL 
cholesterol lowering effect is usually established within the first 2 - 3 weeks and can be sustained by a 
continued consumption of plant sterols/stanols, and that (iv) while plant sterols/stanols added to foods 
such as margarine-type spreads, mayonnaise, salad dressings, and dairy products such as milk, 
yoghurts and cheese have been shown consistently to lower blood LDL-cholesterol, the efficacy of 
plant sterols/stanols added to other food formats is less well established. 
This opinion focuses on the efficacy of 3.0 g per day of plant stanol esters on LDL-cholesterol 
lowering, on the minimum duration for the effect to occur, and on the efficacy in different food 
matrices. 
Throughout this opinion, quantities of sterols and stanol esters are expressed as the equivalent 
weights of free [i.e. un-esterified] stanols. 
2. BLOOD LDL-CHOLESTEROL LOWERING EFFECT OF A DAILY INTAKE OF 3 G PLANT STANOLS 
AS PLANT STANOL ESTERS 
The applicant conducted two literature searches in May 2009 and February 2010 accessing 16 sources 
(Medline®, CAB Abstracts, Allied & Complementary Medicine, MANTIS™, Pascal, Foodline®: 
Science, Global Health, Biosis Previews®, Elsevier Biobase, National Technical Information Service, 
Gale Group Health & Wellness DatabaseSM, EMBASE, New England Journal of Medicine,  Adis 
Clinical Trials Insight, Web of Science,  Cochrane Library). Keywords related to plant sterols and 
stanols (phytosterols), sitosterol, sitostanol, campesterol, campestanol, stigmasterol, brassicasterol, 
blood lipids, cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and human studies. 
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The screening of titles, abstracts and full text articles of in total 3,456 references resulted in the 
identification of 17 treatment arms from 15 studies reported by 12 publications and two unpublished 
study reports which were considered pertinent by the applicant.  
Inclusion criteria were:  randomised controlled trial (parallel or crossover) studies conducted in 
human adults (age >19 years); subjects in the treatment arm received “usual phytostanols” defined as 
4-desmethylsterols and/or 4-desmethylstanols produced from vegetable or plant oils such as soybean 
oil, rapeseed oil, and tall oil;  the active treatment consisted of plant stanol esters (i.e. esterified plant 
stanols comprising ≥ 85 % of total free and esterified plant stanols); for plant stanol/plant sterol 
blends, the proportion of plant stanols was 85 % or more of the plant stanol/plant sterol blend; the 
plant stanol ester was manufactured by (i.e. either provided by or purchased from) Raisio Nutrition 
Ltd.; the target intake administered was between 2.7 to 3.3 g/day of plant stanols (as plant stanol 
ester); the duration of treatment was a minimum of 2 weeks; fasting plasma/serum LDL-cholesterol 
was measured either as a primary or secondary outcome variable; relevant blood lipid data were 
reported or could be calculated; that is, for parallel trials, change from baseline in LDL-cholesterol 
was reported or could be calculated for both the placebo and treatment groups, and for crossover 
studies, LDL-cholesterol at the end of the placebo and active treatments was reported or could be 
calculated; if a co-intervention was administered in the active treatment arm, the co-intervention was 
such that the effects of the plant stanol ester on LDL-cholesterol could be isolated (i.e. the placebo 
group was administered the other intervention, e.g. a statin only). Exclusion criteria were: study was 
not a randomised controlled trial; study was not conducted in adults (where adults is defined as age 
>19 years; study results were reported in abstract form only; studied subjects included colectomised 
patients or subjects who were either homo- or heterozygous for sitosterolemia; the control group was 
not administered a placebo; the active treatment consisted of ferulated phytosterols, such as rice bran 
oil and/or shea nut oil phytosterols; the active treatment consisted of free plant stanols (i.e. esterified 
plant stanols comprised < 85 % of total free and esterified plant stanols); for plant stanol/plant sterol 
blends, the proportion of plant stanols was less than 85 % of the plant stanol/plant sterol blend; the 
plant stanol ester was not manufactured by Raisio Nutrition Ltd; the target dose administered was not 
quantified or was < 2.7 or > 3.3 g/day of plant stanols (as plant stanol ester); the duration of the 
treatment was < 2 weeks; relevant endpoints were not related to fasting LDL-cholesterol; relevant 
blood lipid data were not reported: that is, for parallel trials, change from baseline in LDL-cholesterol 
was not reported and could not be calculated for both the placebo and treatment groups, and for 
crossover studies, LDL-cholesterol at the end of the placebo and active treatments was not reported 
and could not be calculated; the treatment combined plant stanol ester with other nutritional or 
pharmaceutical interventions, the effects of which could not be isolated; the study was a kin 
(duplicate) publication. 
Seventeen randomised controlled treatment arms derived from 12 publications met the selection 
criteria and were analysed via meta-analyses (Raisio, 2011). Eight of the controlled treatment arms 
were derived from cross-over designs; nine of the treatment arms were from parallel studies. In total 
974 subjects were studied. The average age across the 17 treatment arms was 54.2 ± 6.7 years and the 
average fasting baseline LDL-cholesterol was 3.6 ± 0.7 mmol/L (≈ 139 mg/dL). The study 
populations included healthy men and women with a mean age ranging from 36 to 58 years (Miettinen 
et al., 1995 treatment arms 1 and 2; Weststrate and Meijer, 1998 treatment arm 2; Nguyen et al., 1999 
treatment arms 1 and 2; Mensink et al., 2002; Cater et al., 2005: treatment arm 2 of study 1 and study 
2; Alhassan et al., 2006; Mensink et al., 2010); men and women on stable statin therapy (Blair et al., 
2000); men with non-insulin dependent diabetes mellitus (Gylling and Miettinen, 1994; Gylling and 
Miettinen, 1996 treatment arms 1 and 2); post-menopausal women with previous myocardial 
infarction (Gylling et al., 1997 study 1);  men with a positive history for CHD and on stable statin 
therapy (Cater et al., 2005 study 3); and men and women with Type 1 diabetes and receiving statins 
for hypercholesterolemia (Hallikainen et al., 2011).  
The Panel noted that in the original application the applicant had excluded from the meta-analysis the 
study by Homma et al. (2003) which showed a 6.6 % LDL-cholesterol lowering effect with 3g plant 
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stanols on the basis of the exclusion criterion “plant stanol esters not manufactured by Raisio 
Nutrition Ltd”. In response to a request for scientific justification for the exclusion of this study the 
applicant argued that the plant stanol ester preparation used in the Homma-study differed in the 
source of the plant sterols, in its (60:40) ratio of sitostanol:campestanol (different from Raisio‟s plant 
stanol esters which would not contain more than 32 % campestanol) and also in the production 
process (i.e. esterification process) which would lead to higher amounts of isomerisation and 
polymerisation of unsaturated fatty acids (e.g: 6.2 % trans PUFA in the Homma-preparation versus 1 
% in the Raisio plant stanols). The Panel noted that the source of the sterols and the ratio between the 
sitostanol and campestanol do not appear to have a relevant impact on the size of the blood LDL-
cholesterol lowering effect (EFSA, 2009) and considers that this also applies to the small differences 
in the content of trans fatty acids (7.2 % versus 1 %). The Panel also noted that the study by Homma 
et al. (2003) was included by the applicant for its analysis of the continuous dose-response and of the 
“minimum intervention required to achieve the claimed effect”. The Panel therefore requested the 
applicant to include the 3 g/day plant stanol arm of the study by Homma et al. (2003) in the meta-
analysis of 3 g plant stanol ester studies. 
In all of the 18 treatment arms (including Homma et al., 2003) plant stanol esters were used at a daily 
intake of 3 g or slightly less. Seventeen of the 18 treatment arms used spreadable fats as a vehicle and 
one  used yoghurt. The duration of the intervention ranged from 24.5 to 360 days, with the majority (n 
= 12) of treatment arms assessing efficacy within 4 to 7 weeks of the intervention.  Compliance was 
reported for nine treatment arms and ranged between 74 and 100 %.   
Since baseline LDL-cholesterol is known to significantly affect the degree of absolute LDL-
cholesterol lowering (Demonty et al., 2009; Musa-Veloso et al., 2011), the applicant suggested that 
the more appropriate value is the relative reduction in LDL-cholesterol, as baseline LDL-cholesterol 
is accounted for in the relative LDL-cholesterol reduction. When relative (%) placebo-adjusted 
reduction changes and associated variance data were reported in the published articles, these values 
were used. For studies in which relative net changes were not reported, they were calculated from the 
absolute changes.   
The Comprehensive Meta-Analysis Software Version 2.2.050 was used to conduct the meta-analysis. 
The inverse of the variance of the placebo-adjusted mean relative change in LDL was used as a 
weighting factor. In order to obtain variance measures for each study a number of choices were made 
and different methods were applied, based also on what information was available in the original 
papers. Although there might be variability in the level of accuracy of standard deviation estimates 
(subsequently used to calculate variances), due to different sources (calculated in the original study, 
subsequently derived, estimated via Taylor series approximation), linearised approximations for 
variance are a well-established methodology in case of missing information on summary statistics. 
However, the Panel notes the uncertainty deriving from the fact that measures of variability had to be 
computed/estimated for most of the studies (only for 4 treatment arms were the reported original 
relative reductions and associated measures of variability used) and that no sensitivity analysis was 
performed to test the robustness of the imputation of variability parameters (SDs for variance 
calculation). Random effects models were used, given that there was significant heterogeneity 
between the studies as indicated by Hedge‟s q (q = 27.49, df = 16, p = 0.036 and q = 29.23, df = 16, p 
= 0.022, respectively).  
All treatment arms were controlled for a number of potential confounding variables including age, 
baseline LDL-cholesterol levels, health/disease status and medication use; sixteen of the treatment 
arms were controlled for diet, seven treatment arms for alcohol use, four treatment arms for smoking, 
and one treatment arm for physical activity.  
Amongst the 18 treatment arms included in the meta-analyses described above, placebo-adjusted 
LDL-cholesterol reductions ranged from 5.8 % (Nguyen et al., 1999 treatment arm 1) to 20.4 % 
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(Alhassan et al., 2006). The pooled relative reduction in LDL-cholesterol was 11.4 % (95% CI, 9.8 - 
13.0 %).   
The applicant conducted a second post hoc meta-analysis without the treatment arm (Nguyen et al., 
1999) which showed the lowest (5.8 %) relative LDL-cholesterol reduction among all treatment arms. 
The applicant reasoned that in this study conducted in the United States, the treatment arm in which a 
European margarine plant stanol formulation was evaluated had limitations such as a lower 
compliance (74 % versus 88.9 % for the US margarine plant stanol formulation arm and 78.2 % for 
the placebo arm). The applicant also argued that the different formulations of the margarines provided 
different daily amounts of saturated fatty acids: 4.11 g (European margarine) versus 2.25 g (US 
margarine) versus 2.76 g (placebo margarine) and different daily amounts of poly-unsaturated fatty 
acids in the margarine: 3.51 g (European margarine) versus 5.22 g (US margarine) and 5.34 g 
(placebo margarine). After exclusion of the EU margarine-treatment arm of the Nguyen-study, the 
pooled relative reduction in LDL-cholesterol of the 17 treatment arms was 11.9 % (95% CI, 10.60 - 
13.19 %).  The applicant noted that the exclusion of this treatment arm of the Nguyen et al. (1999) 
study eliminated heterogeneity in the meta-analysis, as indicated by hedge‟s q, which was 13.92 (P = 
0.532), and so the fixed effects model was retained. The Panel considers that the small differences in 
the fatty acid composition of the margarines would not affect the study outcome. The Panel notes that 
sensitivity analysis is appropriate when there are outliers but that conclusions should be based on all-
studies analyses, and that the results should be reported. Post-hoc exclusion of a study based on its 
relative contribution to the pooled effect size bears the risk of biasing the overall results. The Panel 
considers that the treatment arm with the European margarine plant stanol formulation should be 
included in the meta-analysis of plant stanol ester studies with 3 g plant stanols per day. The Panel 
also notes that the effect of inclusion or exclusion of the aforementioned treatment arm of the study 
by Nguyen et al. (1999) indicates the sensitivity of the meta-analysis to the inclusion or exclusion of 
individual studies. 
The Panel notes some limitations of the applicant‟s meta-analysis that contribute to uncertainty of the 
estimate of the LDL-cholesterol lowering effect. The study quality of the individual studies was not 
appraised, which was justified by the applicant by referring to the Demonty et al. (2009) meta-
analysis  (141 treatment arms)  where it was concluded that the overall study quality, randomization 
methods and subject compliance had no impact on the parameter estimates of the dose-response 
curve. The Panel considers that this conclusion cannot be extrapolated to a small subset of studies 
included in the meta-analyses by the applicant. Uncertainties derive also from the estimation of the 
relative (%) net changes of LDL-cholesterol levels and variance parameters which were not reported 
in most of the original publications.  
The Panel also notes that the results of the unpublished meta-analysis provided by the applicant are 
comparable to the results of the published meta-analysis by Katan et al. (2003) which showed a 
pooled mean reduction of LDL-cholesterol levels of 11.3 % (95 % CI: 10.2 - 12.3) for ≥ 2.5 g plant 
stanols and sterols consumed daily. The meta-analysis by Katan et al. (2003) comprised 21 treatment 
arms (13 stanol arms, 8 sterol arms; average dose 3.0 g) from five studies with doses between 2.5 and 
2.9 g, 13 studies with doses between 3.0 and 3.4 g, and two studies with 4.0 and 4.2 g phytosterols, 
respectively.     
In order to provide additional evidence that a 12 % reduction of LDL-cholesterol can be achieved by 3 
g of plant stanols per day, the applicant provided another meta-analysis of randomised controlled 
trials which analysed the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a 
continuous dose range (Musa-Veloso et al., 2011). In total, 57 plant stanol ester treatment arms met 
predefined inclusion and exclusion criteria. The relationship between intake of plant stanol esters and 
reduction in LDL-cholesterol was modelled using a first-order elimination curve and fit using the 
nonlinear regression procedure in SAS version 9.0 (SAS Institute), as described by Demonty et al. 
(2009). The dose-response assessment was conducted on LDL-cholesterol measures obtained at the 
time point closest to 4 weeks. Using an equation of the first-order elimination function, the authors 
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retrieved predicted absolute and relative reductions in LDL-cholesterol over a continuous dose range. 
The Panel notes that the dose-response relationship is fitted using average values from the various 
studies. This approach does not take the full variability/uncertainty into consideration. As a 
consequence, the curve does not take into account the full range of variability from individual dose-
response, and the „true‟ variability/uncertainty of the overall dose-response relationship is 
underestimated. Additionally, the correlation between observed and predicted reductions is only 
moderate, suggesting a limited fitting of the model. In fact, the number of observed reductions upon 
which the curve is modelled for higher doses is very small. There is also uncertainty as to what extent 
the imbalance in the amount of evidence (i.e. numbers of studies) across the entire dose range affects 
the shape of the plant stanols curve. The Panel considers that this dose-response analysis does not 
provide useful information for estimating the cholesterol lowering effect of 3 g of plant stanols in 
addition to that obtained from the individual studies and the applicant‟s unpublished meta-analysis. 
The Panel considers that the evidence from randomised controlled human intervention studies of plant 
stanol esters at intakes ranging from 2.7 g to 3.3 g/d in matrices approved by Regulation (EC) No 
376/2010 (yellow fat spreads, dairy products, mayonnaise and salad dressings) shows an average 
pooled LDL-cholesterol reduction of 11.4 % (95% CI: 9.8 – 13.0). 
The Panel could have reached this conclusion without considering the unpublished meta-analysis 
claimed as proprietary by the applicant. 
3. MINIMUM DURATION FOR EFFECT OF PLANT STANOL ESTERS  
The applicant claims that the minimum duration required for efficacy was one to two weeks. To 
determine the minimum duration for efficacy, the applicant searched the 57 plant stanol ester 
treatment arms identified by Musa-Veloso et al. (2011) and identified 11 treatment arms in which 
LDL-cholesterol measurements were made within 2 weeks following the administration of plant 
stanol ester enriched foods. In two (Mensink et al., 2002; Noakes et al., 2005) of three treatment arms, 
in which the earliest LDL-cholesterol measurements was made after one week, the maximum LDL-
cholesterol lowering effect was achieved already after one week of intervention; in the third study 
(Jones et al., 2000) the maximum effect was achieved after two intervention weeks with plant stanols.  
In four (Nguyen et al., 1999, treatment arm 1; Blair et al., 2000; Homma et al., 2003, treatment arms 1 
and 2) out of eight treatment arms in which the earliest LDL-cholesterol measurements were made 
after two weeks of the plant stanol ester intervention the maximum LDL-cholesterol lowering effect 
was attained after two weeks of intervention. In the four other treatment arms (Hallikainen and 
Uusitupa, 1999, treatment arms 1 and 2; Nguyen et al., 1999, treatment arms 2 and 3) most of the 
reduction was already achieved after two weeks.  
The Panel notes that in most of the studies blood LDL-cholesterol was measured the first time only 
after two or three weeks of intervention when the full effect has usually been established. The Panel 
considers that there is insufficient evidence to conclude that the maximum effect is generally achieved 
already after one week and refers to its previous opinion from 2009 when it concluded that the blood 
LDL-cholesterol lowering effect is usually established within the first two to three weeks of 
consumption of stanols (EFSA, 2009).  
The Panel considers that the minimum duration required to achieve the maximum effect of plant 
sterols and stanol esters on LDL-cholesterol lowering is two to three weeks. 
4. EFFICACY OF PLANT STANOL ESTERS IN DIFFERENT FOOD MATRICES  
With regards to the proposed conditions of use, the applicant suggested that the food matrices should 
not be limited to those specified in Regulation (EC) No 376/2010 (European Commission, 2010) 
(yellow fat spreads, dairy products, mayonnaise and salad dressings), and that the claimed effect can 
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also be achieved with other matrices (rye bread, oatmeal, fermented soy milk based products, 
drinkable and spoonable yoghurt-type products, and oat based milk drinks). In response to an EFSA 
request to provide scientific information and/or justification to substantiate that a 12 % reduction of 
LDL-cholesterol is achieved with 3 g/day plant stanols as plant stanol esters added to other food 
matrices, the applicant analysed the 57 plant stanol ester studies identified by Musa-Veloso et al. 
(2011) and provided results for the mean and range of the relative LDL-cholesterol lowering effect 
per gram of plant stanol esters for 31 margarine treatment arms  (4.60 %; 1.92 - 9.31) and for 11 
treatment arms which used other food matrices (mayonnaise, dairy products, salad dressing) specified 
in Regulation (EC) No 376/2010 (4.12 %; 1.32 - 9.68). The Panel notes that all 18 treatment arms 
analysed in the meta-analysis used matrices specified in Regulation (EC) No 376/2010, and that no 
human study has been provided by the applicant to demonstrate that 3 g/d plant stanols consumed 
with other food matrices can lower blood LDL-cholesterol by 12 %. 
The Panel reiterates its previous conclusion (EFSA, 2009) that while plant sterols/stanols added to 
foods such as margarine-type spreads, mayonnaise, salad dressings, and dairy products such as milk, 
yoghurts, including low-fat yoghurts, and cheese have been shown consistently to lower blood LDL-
cholesterol levels, the size of the cholesterol-lowering effect of plant sterols/stanols added to other 
food formats is less well established. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 plant stanol esters at a daily intake of 3 g plant stanols (range 2.7 g to 3.3 g) in matrices 
approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, mayonnaise 
and salad dressings) lowers LDL-cholesterol by 11.4 % (95% CI: 9.8 – 13.0). 
 the minimum duration required to achieve the maximum effect of plant stanol esters on LDL-
cholesterol lowering is two to three weeks. 
 while plant stanol esters added to foods such as margarine-type spreads, mayonnaise, salad 
dressings, and dairy products such as milk, yoghurts including low-fat yoghurts, and cheese 
have been shown consistently to lower blood LDL-cholesterol levels, the size of the 
cholesterol-lowering effect of plant sterols/stanols added to other food formats is less well 
established. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on plant stanol esters and blood cholesterol pursuant to Article 14 of 
Regulation (EC) No 1924/2006 (Claim serial No: 0307_FI). June 2011. Submitted by Raisio Nutrition 
Ltd. 
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GLOSSARY / ABBREVIATIONS 
CHD  Coronary heart disease 
LDL  Low density lipoproteins  
